21802_CROSSROADS OF CARE: Facing the Challenges of Heart Failure and Diabetes

In this symposium, Dr. James Januzzi and Dr. Mikhail Kosiborod will explain the intertwined relationship between diabetes and HF, and interpret safety and effi cacy data, focusing on HF-related outcomes, from studies with diabetes therapies.

The prevalence of patients with concomitant heart failure (HF) and diabetes
mellitus (DM) continues to increase with the general aging of the population.
Patients with concomitant HF and DM have diverse pathophysiologic,
metabolic, and neurohormonal abnormalities that potentially contribute
to worse outcomes than those without comorbid DM. The relationship
between DM and HF is bidirectional, with each disease independently
increasing the risk for the other. Benefits in HF-related outcomes have
been demonstrated with diabetes therapies, specifi cally SGLT2 inhibitors,
in cardiovascular outcome trials (CVOTs) and in large multinational studies of
“real-world” practice. Therefore, it is important for cardiovascular clinicians
to be aware of these fi ndings, and also HF-related outcomes results from
CVOTs involving other classes of diabetes therapies, in order to improve
their assessment of benefit/risk of diabetes therapies for cardiovascular risk
reduction. In this symposium, Dr. James Januzzi and Dr. Mikhail Kosiborod
will explain the intertwined relationship between diabetes and HF, and
interpret safety and efficacy data, focusing on HF-related outcomes, from
studies with diabetes therapies.

Login to your Account